Biomarkers Expand Precision in CRC
-
By
February 6, 2026
-
5 min
-
1
Established biomarkers like KRAS and MSI are critical in CRC management.
-
2
Emerging noninvasive tests include multitarget stool DNA and ctDNA assays.
-
3
Multi-omics integration aids in prognostic model development.
-
4
Predictive factors such as RAS mutations guide treatment selection.
-
5
Future challenges include validation trials and assay standardization.
-
6
Personalized CRC care can enhance patient outcomes through tailored interventions.
-
Advancements in diagnostic, prognostic, and predictive biomarkers are transforming the management of colorectal cancer (CRC). Grounded in a narrative review by Alfonso Agüera-Sánchez and colleagues, established markers like KRAS mutations and MSI status are foundational in personalized CRC therapy. Emerging biomarkers, including circulating tumor DNA and microbiome analysis, are enhancing noninvasive detection techniques. The integration of multi-omics is shaping prognosis and treatment adaptation, with ongoing studies aimed at refining clinical outcomes. The future emphasizes the urgent need for validation and standardization.
-
1
Established biomarkers like KRAS and MSI are critical in CRC management.
-
2
Emerging noninvasive tests include multitarget stool DNA and ctDNA assays.
-
3
Multi-omics integration aids in prognostic model development.
-
4
Predictive factors such as RAS mutations guide treatment selection.
-
5
Future challenges include validation trials and assay standardization.
-
6
Personalized CRC care can enhance patient outcomes through tailored interventions.
Listen Tab content
